Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
September 15, 2023 05:36 ET
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer...
Les actionnaires de Novartis approuvent le projet de scission à 100% de Sandoz
September 15, 2023 05:36 ET
|
Novartis Pharma AG
Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le...
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
September 15, 2023 05:36 ET
|
Novartis Pharma AG
Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off...
Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
September 11, 2023 01:15 ET
|
Novartis Pharma AG
Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to interleukin...
Novartis nomme Patrick Horber, Docteur en médecine, au poste de President, International, alors que Marie-France Tschudin, President, Innovative Medicines International et Chief Commercial Officer, quitte le Comité exécutif de Novartis
September 06, 2023 01:15 ET
|
Novartis Pharma AG
Après près de sept années chez Novartis et plus de quatre années en tant que membre du Comité exécutif de Novartis, Mme Tschudin poursuivra sa carrière de leader en dehors de Novartis Le Dr Horber...
Novartis ernennt Dr. Patrick Horber zum President, International, da Marie-France Tschudin, President, Innovative Medicines International und Chief Commercial Officer, aus der Geschäftsleitung von Novartis ausscheidet
September 06, 2023 01:15 ET
|
Novartis Pharma AG
Nach fast sieben Jahren bei Novartis und mehr als vier Jahren als Mitglied der Geschäftsleitung wird Marie-France Tschudin ihr nächstes Führungskapitel ausserhalb von Novartis beginnen Dr. Horber...
Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis
September 06, 2023 01:15 ET
|
Novartis Pharma AG
After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase...
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
August 28, 2023 08:15 ET
|
Novartis Pharma AG
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six years...
Novartis completes acquisition of Chinook Therapeutics
August 11, 2023 11:30 ET
|
Novartis Pharma AG
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin A...
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
August 09, 2023 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across...